Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment

SIMPLE SUMMARY: Tyrosine kinase inhibitors (TKI), such as imatinib, nilotinib, and dasatinib, are the first-line treatment of choice for patients with chronic myeloid leukemia (CML). However, patients may develop serious cardiovascular events (CVE) with their use. Cardiotoxicity is an important issu...

Descripción completa

Detalles Bibliográficos
Autores principales: Stuckey, Ruth, Segura-Díaz, Adrián, Sáez Perdomo, María Nieves, Pérez Encinas, Manuel Mateo, González San Miguel, Jóse David, Florido, Yanira, Sánchez-Sosa, Santiago, López-Rodríguez, Juan Francisco, Bilbao-Sieyro, Cristina, Gómez-Casares, María Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341219/
https://www.ncbi.nlm.nih.gov/pubmed/37444494
http://dx.doi.org/10.3390/cancers15133384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341219/
https://www.ncbi.nlm.nih.gov/pubmed/37444494
http://dx.doi.org/10.3390/cancers15133384

Ejemplares similares